



L-131 Development Plan
Pediatric Anxiety

October 11, 2023

L-131: Orphan Pediatric Indication(s)


Undisclosed Orphan Drug Indication with Voucher Possible

- *L-131: A New Chemical Entity (NCE) with Patents filed in 2022*
- *Established Schedule 1 manufacturing under GMP conditions in the US*
- *Differentiated psilocin conjugate formulated for pediatric use*
 - *Physical and chemical characteristics are favorable for specialized formulation development (oral liquid or suspension for children)*

L-131: Clinical Development

- | | |
|--|----------------|
| • <i>IND-enabling study (Pre-Clinical) to be initiated</i> | Q4 2023 |
| • <i>Orphan drug application (pediatric) in preparation</i> | H1 2024 |
| • <i>Phase I “first in man” trial to determine safety and pharmacokinetics</i> | H2 2024 |
| • <i>Eligible for Pediatric Priority Review Voucher (PRV)</i> | TBD |

L-130/ L-131 Development Timelines



Thank You

Contact: info@lobesciences.com

www.lobesciences.com